Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03391960 · ClinicalTrials.gov registry record · NA
Passive Disinfection Cap Compliance Study
A NA study of Infection, Hospital, sponsored by Solventum US.
- Completed
- Registry status
- NA
- Development phase
- 165
- Enrollment target
- 1
- Study location
NCT03391960: Completed NA study of Infection, Hospital, sponsored by Solventum US.
NCT03391960 is a NA study of Infection, Hospital that has completed, run by Solventum US. The registered enrollment target is 165 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03391960, a NA study of Infection, Hospital, has completed, sponsored by Solventum US.
- COMPLETED
- Registry status
- NA
- Development phase
- 165 participants
- Enrollment target
- 1
- Study location
Study Summary
Insertion and maintenance of central venous catheter (CVC) lines are common hospital procedures in patients, including those being treated for cancer. CVCs allow clinicians an access point for infusion of fluids, blood sampling, and measurements, decreasing the need for repeated needle sticks to the patient. However, bloodstream infections associated with CVCs (CLABSIs) are a serious complication, leading to significantly longer hospital stays, morbidity, and mortality. Keeping catheter ports disinfected reduces the risk of bloodstream infection; however, consistent and adequate maintenance and disinfection of the line can be difficult. The purpose of this study is to demonstrate that passive disinfecting caps can provide a patient safety practice that is easy for clinicians to follow, as well as providing easily auditable compliance, which may lead to lower CLABSI rates. The compliance rate for needleless connector disinfection will be evaluated after implementation of the passive disinfecting cap, and compared to the pre-intervention rate. The CLABSI rates before and after cap implementation will also be compared.
Primary Outcome
Compliance to disinfection protocol for central line needleless connectors. Compliance will be measured by periodic audits, where the number of disinfecting caps on central line needleless connectors is compared to the total number of central line needleless connectors to determine compliance percentage.
Conditions Studied
Interventions
- DEVICE Passive disinfection device
Study Locations (1)
Minnesota
- 3M HealthCare - Maplewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2018-04-01 |
| Est. Completion | 2018-10-31 |
| Phase | NA |
What the finished NCT03391960 record still lists
NCT03391960 is an interventional study that assigns participants to a tested intervention. The registered 165 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Infection, Hospital appearing as the primary indexed condition, and to 1 intervention - of which Passive disinfection device is the first listed.
NCT03391960 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03391960 about?
NCT03391960 is a clinical study titled "Passive Disinfection Cap Compliance Study". Insertion and maintenance of central venous catheter (CVC) lines are common hospital procedures in patients, including those being treated for cancer. CVCs allow clinicians an access point for infusion of fluids, blood sampling, and measurements, decreasing the need for repeated needle sticks to the...
What is the current status of trial NCT03391960?
This trial is currently completed. It is a NA study. The enrollment target is 165 participants. The study started on 2018-04-01. Estimated completion is 2018-10-31.
What conditions does trial NCT03391960 study?
This clinical trial studies the following conditions: Infection, Hospital.
What interventions are being tested in trial NCT03391960?
The interventions under investigation include: Passive disinfection device (DEVICE).
Who is sponsoring clinical trial NCT03391960?
This trial is sponsored by Solventum US, which has 41 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03391960 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03391960's enrollment target sits among peer trials
165 626th of 2000 higher than 1,375 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02387255 · 165 participants
Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms
- NCT03351348 · 165 participants · Phase 3
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
- NCT03830320 · 165 participants · Phase 1
Positron Emission Tomography (PET) Imaging of Thrombosis
- NCT04289571 · 165 participants · Phase 1
Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI